MTA3 and breast carcinoma: Through preclinical studies and preliminary translational research, the potential of MTA3 as a prognostic biomarker or therapeutic target could be cautiously assessed, thereby providing a foundational theoretical basis and guiding future research directions for the precision treatment of breast cancer.